Literature DB >> 31545245

Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma.

Hongwei Zhang1, Lixia Zhang2, Yumin Tang1, Chaoji Wang1, Yiding Chen1, Jinjun Shu1, Kexian Zhang3.   

Abstract

Currently, no reliable prognostic biomarkers have been identified for adult IDH wild-type (WT) diffuse low grade glioma (LGG). With data from The Cancer Genome Atlas (TCGA)-LGG, we examined the prognostic value of GABAA receptor subunits in adult IDH WT LGG. Using 2016 WHO CNS tumor classification, we re-classified the TCGA-LGG and identified 95 IDH WT patients. Among 16 GABAA receptor subunit genes with RNA-seq data, eight genes showed significantly different expression in IDH WT LGG compared with IDH mutant (MT) cases. Among these genes, only GABRD expression was related to overall survival (OS) status. Preserved GABRD expression was independently associated with longer OS (HR: 0.799, 95%CI: 0.691-0.925, p = 0.003) in IDH WT LGG. GABRD expression showed a moderately negative correlation with tumor infiltration macrophage (TIM) and CSF1 expression. The methylation status of 34 CpG sites across GABRD gene was checked and only cg13916816 showed a moderately negative correlation with GABRD expression. In conclusion, GABRD expression might serve as a potential independent prognostic marker in patients with IDH WT LGG. Meanwhile, its expression was negatively correlated with the extent of TIM, which might help to explain the favorable survival outcome. Cg13916816 might be a critical CpG site influencing GABRD expression in IDH WT LGG.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  GABRD; IDH mutation; Low grade glioma; Prognosis

Mesh:

Substances:

Year:  2019        PMID: 31545245     DOI: 10.1016/j.biopha.2019.109215

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  Prognostic significance of ARL9 and its methylation in low-grade glioma.

Authors:  Yutang Tan; Suojun Zhang; Qungen Xiao; Junwen Wang; Kai Zhao; Weihua Liu; Kuan Huang; Weidong Tian; Hongquan Niu; Ting Lei; Kai Shu
Journal:  Genomics       Date:  2020-08-31       Impact factor: 5.736

2.  Role of GABRD Gene Methylation in the Nucleus Accumbens in Heroin-Seeking Behavior in Rats.

Authors:  Qingxiao Hong; Wenjin Xu; Zi Lin; Jing Liu; Weisheng Chen; Huaqiang Zhu; Miaojun Lai; Dingding Zhuang; Zemin Xu; Dan Fu; Wenhua Zhou; Huifen Liu
Journal:  Front Pharmacol       Date:  2021-01-21       Impact factor: 5.810

3.  Identification of Core Genes and Screening of Potential Targets in Glioblastoma Multiforme by Integrated Bioinformatic Analysis.

Authors:  Ji'an Yang; Qian Yang
Journal:  Front Oncol       Date:  2021-02-24       Impact factor: 6.244

4.  Validation of the functions and prognostic values of synapse-associated proteins in lower-grade glioma.

Authors:  Yong Yang; Chongxian Hou; Yuqing Huang; Han Lin; Liting Zhou; Jiantao Zheng; Guangzhao Lv; Rui Mao; Shanwei Chen; Peihong Xu; Yujun Zhou; Peng Wang; Dong Zhou
Journal:  Biosci Rep       Date:  2021-05-28       Impact factor: 3.840

5.  Clinical Data and Biocalculation Methods of GABRD Determine the Clinical Characteristics and Immune Relevance of Colorectal Cancer.

Authors:  Yuhe Bi; Xinju Liu; Wei Li; JiaCheng Xu; Jie Xi; Shengchao Wei
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-21       Impact factor: 2.650

6.  Enhanced expression of GABRD predicts poor prognosis in patients with colon adenocarcinoma.

Authors:  Moxin Wu; Keun Young Kim; Won Cheol Park; Han-Seung Ryu; Suck Chei Choi; Min Seob Kim; Ji Yeon Myung; Hyun Seok Choi; Eui Joong Kim; Moon Young Lee
Journal:  Transl Oncol       Date:  2020-09-03       Impact factor: 4.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.